{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:17Z","timestamp":1792496237823,"version":"4.5.0"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1161\/circulationaha.111.028381","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T20:40:25Z","timestamp":1335818425000},"page":"2156-2164","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":92,"title":["Food and Drug Administration's Obesity Drug Guidance Document"],"prefix":"10.1161","volume":"125","author":[{"given":"Eric","family":"Colman","sequence":"first","affiliation":[{"name":"From the Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1549"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.79"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.16.1867"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.171016"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0139-7"},{"key":"e_1_3_2_7_2","first-page":"595","article-title":"Overweight, gender, and knee osteoarthritis","volume":"20","author":"Manninen P","year":"1996","unstructured":"Manninen P, Riihimaki H, Heliovaara M, Makela P . Overweight, gender, and knee osteoarthritis. Int J Obes Relat Metab Disord. 1996; 20: 595\u2013 597.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/157339709790192440"},{"key":"e_1_3_2_9_2","first-page":"187","article-title":"Epidemiology of obstructive sleep apnea syndrome","volume":"95","author":"Ferini-Strambi L","year":"2004","unstructured":"Ferini-Strambi L, Fantini ML, Castronovo C . Epidemiology of obstructive sleep apnea syndrome. Minerva Med. 2004; 95: 187\u2013 202.","journal-title":"Minerva Med"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.636"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.169"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00013"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.110593"},{"key":"e_1_3_2_14_2","first-page":"981","article-title":"Health implications of obesity: National Institutes of Health Consensus Development Conference","volume":"103","year":"1985","unstructured":"Health implications of obesity: National Institutes of Health Consensus Development Conference. Ann Intern Med. 1985; 103: 981\u2013 982.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/372425a0"},{"key":"e_1_3_2_16_2","unstructured":"US Food and Drug Administration. Proceedings of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring MD: US Food and Drug Administration; 1995."},{"key":"e_1_3_2_17_2","volume-title":"Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting","author":"Bray G","unstructured":"Bray G . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; January 19\u201320, 1995; Silver Spring, MD"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/54.2.321"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91499-2"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.76"},{"key":"e_1_3_2_21_2","volume-title":"Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting","author":"Cara J","unstructured":"Cara J . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; January 19\u201320, 1995; Silver Spring, MD."},{"key":"e_1_3_2_22_2","volume-title":"Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting","author":"Siris E","unstructured":"Siris E . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; January 19\u201320, 1995; Silver Spring, MD."},{"key":"e_1_3_2_23_2","volume-title":"Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting","author":"Troendle G","unstructured":"Troendle G Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; January 19\u201320, 1995; Silver Spring, MD."},{"key":"e_1_3_2_24_2","unstructured":"US Food and Drug Administration. 1996 Guidelines for the Clinical Evaluation of Weight-Control Drug. Silver Spring MD: US Food and Drug Administration; 1996."},{"key":"e_1_3_2_25_2","first-page":"155","article-title":"Health implications of obesity: an NIH consensus development conference","volume":"85","author":"Burton B","year":"1985","unstructured":"Burton B, Foster W, Hirsch J, Van Itallie T . Health implications of obesity: an NIH consensus development conference. Int J Obes. 1985; 85: 155\u2013 169.","journal-title":"Int J Obes"},{"key":"e_1_3_2_26_2","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein D","year":"1992","unstructured":"Goldstein D . Beneficial health effects of modest weight loss. Int J Obes. 1992; 16: 397\u2013 415.","journal-title":"Int J Obes"},{"key":"e_1_3_2_27_2","unstructured":"US Food and Drug Administration. Medical officer review of dexfenfluramine. 1995. New Drug Application No. 20-344."},{"key":"e_1_3_2_28_2","unstructured":"US Food and Drug Administration. Medical officer review of sibutramine. 1996. New Drug Application No. 20-632; 1996."},{"key":"e_1_3_2_29_2","unstructured":"US Food and Drug Administration. Medical officer review of orlistat. 1999. New Drug Application No. 20-766."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199652050-00007"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.8"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00019"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92301-H"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"e_1_3_2_35_2","volume-title":"Proceedings of the Endocrinologic and Metabolic Drugs Advisory Committee MeetingUS Food and Drug Administration","author":"US Food and Drug Administration.","year":"1995","unstructured":"US Food and Drug Administration. Proceedings of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring, MD: US Food and Drug Administration; 1995."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04230.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04180.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_3_2_39_2","unstructured":"FDA announces withdrawal fenfluramine and dexfenfluramine. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm179871.htm. Accessed July 6 2011."},{"key":"e_1_3_2_40_2","unstructured":"Clinical Guidelines on the Identification Evaluation and Treatment of Overweight and Obesity in Adults: Public Health Service. Bethesda MD: National Institutes of Health National Heart Lung and Blood Institute; 1998. NIH publication No. 98-4083."},{"key":"e_1_3_2_41_2","first-page":"1","article-title":"Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee","volume":"854","author":"World Health Organization.","year":"1995","unstructured":"World Health Organization. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995; 854: 1\u2013 452.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390030083026"},{"key":"e_1_3_2_43_2","first-page":"63","article-title":"The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies","volume":"1","author":"Troiano R","year":"1996","unstructured":"Troiano R, Frongillo E, Sobal J, Levisky D . The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord. 1996; 1: 63\u2013 75.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_3_2_44_2","unstructured":"US Food and Drug Administration. Proceedings of the Endocrinologic and Metabolic Drugs Advisory Committee. Silver Spring MD: US Food and Drug Administration; 2004."},{"key":"e_1_3_2_45_2","unstructured":"Flegal K . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; September 8 2004; Silver Spring MD."},{"key":"e_1_3_2_46_2","unstructured":"Atkinson R . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; September 8 2004; Silver Spring MD."},{"key":"e_1_3_2_47_2","unstructured":"Wierman M . Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; September 8 2004; Silver Spring MD."},{"key":"e_1_3_2_48_2","unstructured":"US Food and Drug Administration. Developing products for weight management: draft guidance. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm064981.htm. Accessed July 6 2011."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.2.160"},{"key":"e_1_3_2_50_2","unstructured":"Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention: draft guidance. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071624.pdf. Accessed October 28 2011."},{"key":"e_1_3_2_51_2","unstructured":"Diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071627.pdf. Accessed October 28 2011."},{"key":"e_1_3_2_52_2","unstructured":"Fixed-combination prescription drugs for humans. Code of Federal Regulations. Title 21 Pt 300.50 2011."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450043490514"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001"},{"key":"e_1_3_2_55_2","unstructured":"McDonagh M Peterson K Carson S Fu R Thakurta S Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report. Portland OR: Oregon Health and Science University; 2010."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-200209000-00007"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald L","year":"2000","unstructured":"Fitzgerald L, Burn T, Brown B, Patterson J, Corjay M, Valentine P, Sun J, Link J, Abbaszade I, Hollis J, Largent B, Hartig P, Hollis P, Meunier P, Robichaud A, Robertson D . Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000; 57: 75\u2013 81.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-0009"},{"key":"e_1_3_2_59_2","unstructured":"US Food and Drug Administration. Briefing Document for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring MD: US Food and Drug Administration; June 13 2007."},{"key":"e_1_3_2_60_2","unstructured":"US Food and Drug Administration. Transcript for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting; Silver Spring MD: US Food and Drug Administration; June 13 2007."},{"key":"e_1_3_2_61_2","unstructured":"European Medicines Agency. Public statement on Accomplia (rimonabant). Withdrawal of the marketing authorization in the European Union. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/11\/WC500012189.pdf. Accessed April 8 2012."},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60935-X"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_3_2_64_2","unstructured":"US Food and Drug Administration. Transcript for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring MD: US Food and Drug Administration; September 15 2010."},{"key":"e_1_3_2_65_2","unstructured":"US Food and Drug Administration. Transcript for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring MD: US Food and Drug Administration; September 15 2010."},{"key":"e_1_3_2_66_2","first-page":"CD004095","article-title":"Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus","author":"Norris S","year":"2005","unstructured":"Norris S, Zhang X, Avenell A, Gregg E, Schmid C, Lau J . Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005: CD004095.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00167308"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.05.002"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100824"},{"key":"e_1_3_2_70_2","unstructured":"Memorandum to the file NDA 20-632 Meridia (sibutramine hydrochloride monohydrate). October 4 2010. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM228795.pdf. Accessed July 6 2011."},{"key":"e_1_3_2_71_2","unstructured":"Abbott to voluntarily withdraw Meridia (sibutramine) in the U.S. http:\/\/www.abbott.com\/news-media\/press-releases\/Press_Release_0908.htm. Accessed April 8 2012."},{"key":"e_1_3_2_72_2","unstructured":"Availability for public disclosure of data and information in an application or abbreviated application. Code of Federal Regulations. Title 21 Pt 314.430 (d)(1)."},{"key":"e_1_3_2_73_2","volume-title":"Proceedings From the Endocrinologic and Metabolic Drugs Advisory Committee Meeting","author":"US Food and Drug Administration.","unstructured":"US Food and Drug Administration. Proceedings From the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM224180.pdf. Accessed October 20, 2011."},{"key":"e_1_3_2_74_2","unstructured":"US Food and Drug Administration. Proceedings from the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM232443.pdf. Accessed October 20 2011."},{"key":"e_1_3_2_75_2","unstructured":"US Food and Drug Administration. Proceedings from the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM239926.pdf. Accessed October 20 2011."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.82"},{"key":"e_1_3_2_77_2","article-title":"Obesity reset","author":"McCallister E","unstructured":"McCallister E Obesity reset. Biocentury. http:\/\/www.biocentury.com\/promotions\/obesity\/next-generation-of-obesity-drugs-unlikely-to-reach-regulators-before-2014.htm. Accessed April 8, 2012.","journal-title":"Biocentury"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.111.028381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T23:26:34Z","timestamp":1743031594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.111.028381"}},"subtitle":["A Short History"],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":76,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.111.028381"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.111.028381","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"2012-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}